The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

被引：0
作者：
Francesca Forzano
Olga Antonova
Angus Clarke
Guido de Wert
Sabine Hentze
Yalda Jamshidi
Yves Moreau
Markus Perola
Inga Prokopenko
Andrew Read
Alexandre Reymond
Vigdis Stefansdottir
Carla van El
Maurizio Genuardi
机构：
[1] Guy’s and St Thomas NHS Foundation Trust,Clinical Genetics Department
[2] Medical University of Sofia,Department of Medical Genetics
[3] Cardiff University,Division of Cancer and Genetics, School of Medicine
[4] Maastricht University,Genetics Research Centre, Molecular and Clinical Sciences Institute
[5] Human Genetics,Department of Clinical & Experimental Medicine
[6] St George’s University of London,UMR 8199
[7] University of Leuven ESAT-STADIUS, EGID, Institut Pasteur de Lille, CNRS
[8] Finnish Institute for Health and Welfare (THL),Institute of Biochemistry and Genetics
[9] Biomedicum 1,Center for Integrative Genomics
[10] University of Surrey,Department of Genetics and Molecular Medicine
[11] University of Lille,Section Community Genetics, Department of Clinical Genetics and Amsterdam Public Health Research Institute, Amsterdam UMC
[12] Ufa Federal Research Centre,UOC Genetica Medica, Dipartimento di Scienze di Laboratorio e Infettivologiche
[13] Russian Academy of Sciences,Sezione di Medicina Genomica, Dipartimento di Scienze della Vita e Sanità Pubblica
[14] Centre for Genomic Medicine,Clinical Institute for Genomic Medicine
[15] St Mary’s Hospital,Department of Pathology, Faculty of Medicine
[16] University of Lausanne,Instituto de Investigação e Inovação em Saúde (i3S)
[17] Landspitali University Hospital,Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup)
[18] Vrije Universiteit Amsterdam,Department of Medical Genetics
[19] Fondazione Policlinico Universitario A. Gemelli IRCCS,Researcher Medical Ethics
[20] Università Cattolica del Sacro Cuore,Department of Biology and Medical Genetics, 2nd Faculty of Medicine
[21] University Medical Center Ljubljana,Department of Medical Genetics
[22] University of Porto,UnIGENe and Centre for Predictive and Preventive Genetics, IBMC—Institute for Molecular and Cell Biology, i3S—Instituto de Investigação e Inovação em Saúde
[23] PT,Laboratory for Molecular Biology, Institute of Molecular Genetics and Genetic Engineering
[24] University of Porto,CERPOP, UMR 1295, Inserm
[25] PT,Plateforme Sociétale “Génétique et Société, GIS Genotoul
[26] University of Porto,Manchester Centre of Health Psychology, Division of Psychology and Mental Health, School of Health Sciences
[27] PT,undefined
[28] Haukeland University Hospital,undefined
[29] Department of Genetics,undefined
[30] SYNLAB Suisse SA,undefined
[31] Lund University,undefined
[32] Chalmers University (part of GENIE initiative),undefined
[33] Charles University and Motol University Hospital,undefined
[34] University of Pécs,undefined
[35] Universidade do Porto,undefined
[36] University of Belgrade,undefined
[37] CERPOP,undefined
[38] UMR 1295,undefined
[39] Inserm,undefined
[40] Université de Toulouse-Université Paul Sabatier-Toulouse III,undefined
[41] Responsable Equipe BIOETHICS: Trajectoires d’innovations en santé:enjeux bioéthiques et sociétaux,undefined
[42] Génopole Toulouse Midi-Pyrénées,undefined
[43] Manchester Academic Health Science Centre,undefined
[44] University of Manchester,undefined
来源：
European Journal of Human Genetics | 2022年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.
引用
收藏
页码：493 / 495
页数：2
相关论文
共 25 条
[1]  
Turley P(2021)Problems with using polygenic scores to select embryos N Engl J Med 2021 78-86
[2]  
Meyer MN(2019)Polygenic risk scores that predict common diseases using millions of single nucleotide polymorphisms: is more, better? Clin Chem 65 5-7
[3]  
Wang N(2019)The illusion of polygenic disease risk prediction Genet Med 21 1705-7
[4]  
Cesarini D(2019)Evaluation of polygenic risk models using multiple performance measures: a critical assessment of discordant results Genet Med 21 391-undefined
[5]  
Hammonds E(2020)Polygenic risk scores: from research tools to clinical instruments Genome Med 12 l5688-undefined
[6]  
Martin AR(2019)Direct-to-consumer genetic testing BMJ. 367 undefined-undefined
[7]  
Janssens ACJW(2021)Polygenic risk scoring of human embryos: a qualitative study of media coverage BMC Med Ethics 22 undefined-undefined
[8]  
Joyner MJ(undefined)undefined undefined undefined undefined-undefined
[9]  
Wald NJ(undefined)undefined undefined undefined undefined-undefined
[10]  
Old R(undefined)undefined undefined undefined undefined-undefined
123